@RuthLopert @kchalkidou There is a place for thinking about cost: for many orphan drugs prices are far above standard cost-effectiveness thresholds. Risk-adjusted costs present at least an upper bound on pricing. https://t.co/gXrNMyufAK
1,432 followers
2,027 followers
RT @aidanhollis: @OHENews @MBerdud This helpful paper by @MBerdud et al continues to develop the argument that average costs may be relevan…
268 followers
Thanks @aidanhollis. The full paper is now available at: https://t.co/GtKsMeAjz4
1,432 followers
@OHENews @MBerdud This helpful paper by @MBerdud et al continues to develop the argument that average costs may be relevant for setting a *cap* on orphan drug prices, first advanced by @GK_Fellows and me https://t.co/gXrNMyufAK